PP2B and ERK1/2 regulate hyaluronan synthesis of HT168 and WM35 human melanoma cell lines by Mészár,-Katona Éva et al.
INTERNATIONAL JOURNAL OF ONCOLOGY  48:  983-997,  2016
Abstract. Hyaluronan (HA) is the major glycosaminoglycan 
component of the extracellular matrix in either normal or 
malignant tissues and it may affect proliferation, motility 
and differentiation of various cell types. Three isoforms of 
plasma membrane-bound hyaluronan synthases (HAS 1, 2 
and 3) secrete and simultaneously bind pericellular HA. HAS 
enzymes are subjects of post-translational protein phosphory-
lation which is believed to regulate their enzymatic activity. 
In this study, we investigated the HA homeostasis of normal 
human epidermal melanocytes, HT168 and WM35 human 
melanoma cell lines and melanoma metastases. HAS2 and 
HAS3 were detected in all the samples, while the expression of 
HAS1 was not detectable in any case. Malignant tissue samples 
and melanoma cell lines contained extra- and intracellular HA 
abundantly but not normal melanocytes. Applying HA as a 
chemoattractant facilitated the migration of melanoma cells 
in Boyden chamber. The amount of HA was reduced upon the 
inhibition of calcineurin with cyclosporine A (CsA), while 
the inhibition of ERK1/2 with PD098059 elevated it in both 
cell lines. The signals of Ser/Thr phosphoproteins at 57 kD 
were stronger after CsA treatment, while a markedly weaker 
signal was detected upon inhibition of the MAPK pathway. 
Our results suggest opposing effects of the two investigated 
enzymes on the HA homeostasis of melanoma cells. We 
propose that the dephosphorylation of HAS enzymes targeted 
by PP2B augments HA production, while their phosphoryla-
tion by the activity of MAPK pathway reduces HA synthesis. 
As the expression of the HA receptor RHAMM was also 
significantly enhanced by PD098059, the MAPK pathway 
exerted a complex attenuating effect on HA signalling in the 
investigated melanoma cells. This observation suggests that 
the application of MAPK-ERK pathway inhibitors requires 
a careful therapeutic design in melanoma treatment.
Introduction
Cutaneous malignant melanoma is a highly aggressive tumour 
originating from melanocytes situated in the stratum basale of 
the epidermis (1). Malignant transformation of melanocytes 
can be induced endogenously via genetic predisposition or 
by exogenous factors such as UV irradiation. In either case, 
alterations in the composition of pericellular matrix and/or 
cell surface receptor pattern could occur. It is widely accepted, 
that any modulation of the cell-matrix interaction may trigger 
changes in the activity of various signalling pathways leading to 
uncontrolled cellular proliferation or motility (2-4). Hyaluronic 
acid (HA) is a non-sulphated high-molecular-mass glycos-
aminoglycan (GAG) built by disaccharide units composed of 
N-acetyl-glucosamine and glucuronic acid. HA is the most 
abundant component of the extracellular matrix either in normal 
or malignantly transformed tissues. Polyanionic character of 
HA may provide a highly hydrated, anti-adhesive pericellular 
matrix to malignantly transformed cells, including melanoma 
cells, playing a critical role in the invasion of surrounding tissues 
(5). Three isotypes of HA synthases (HAS) HAS1, HAS2, and 
HAS3 are responsible for the production of HA (6,7). HAS are 
transmembrane molecules producing HA extruded into the 
extracellular space and they also connect it to the cells in the 
meantime. Major differences of the isoforms are in the length 
of the HA produced and the ease of the release (7-10). HAS1 
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and HAS2 produce higher molecular mass (106 Da) HA chains 
forming a pericellular HA coat, while HA produced by HAS3 
is shorter (105 Da) (11,12). Besides the synthesising enzymes, 
pericellular HA also binds to cell surface receptors, of which 
CD44 is the best known, but an atypical variant of hyalad-
herins, RHAMM (receptor for hyaluronan mediated motility), 
also plays an important role in cell-HA interactions (13,14). 
RHamm fulfils primarily intracellular functions but may also 
appear in the plasma membrane, where it acts as a co-receptor 
for HA together with CD44. It is worth to mention, that presence 
of extracellular RHAMM is very frequent on highly malignant, 
invasive, metastatic tumour cells (15). Engagement of CD44 
and RHAMM with HA can modulate motility and invasion of 
tumour cells (14), and may activate a great variety of signalling 
cascades (16). It is also known, that cells can incorporate small 
HA oligosaccharide particles by endocytosis (17) and intracel-
lular Ha may influence activity of various signal transduction 
pathways regulating proliferation, adhesion and motility either 
in normal or malignantly transformed cells (18-20). It has been 
published that a direct intracellular interaction of RHAMM 
and HA can activate ERK1/2 and can result in a consequent 
enhancement of cell proliferation (21).
Signalling elements connected to the HA homeostasis of 
tumour cells can be activated by reversible phosphorylation 
on Ser/Thr amino acid residues by several protein kinases 
such as PKA, classical PKCs (22) or Ras (23). It has also been 
reported that enzymatic activity of HAS2 and HAS3 isotypes 
are regulated by Ser/Thr phosphorylation (21). In contrast, little 
is known about the role of phosphoprotein phosphatases (PP) 
which can dephosphorylate the target proteins in the regula-
tion of HA synthesis or binding of HA by cells. Calcineurin 
or PP2B is a Ca2+-calmodulin-dependent ser/Thr specific PP, 
which is present in the majority of mammalian cells and tissues 
(24). The presence of PP2B in epidermis-related cells, such as 
keratinocytes and melanocytes was reported only few years ago 
(25,26). Importance of PP2B in skin homeostasis is proved by 
the fact, that pharmacological inhibitors of this PP are applied 
in the dermatological practice for topic treatment of various 
inflammatory diseases of skin accompanied with activation 
of T-lymphocytes, e.g., atopic dermatitis (27). Our group has 
proven that calcineurin influenced migration of melanoma cells 
(28) but the connection of this PP and HA homeostasis has not 
been investigated yet.
In this study we provide evidence that unlike the melano-
cytes, HA is abundantly produced by melanoma cells and serves 
as a chemoattractant for their migration in Boyden chamber. 
HAS2 and HAS3 enzymes were detectable in melanoma metas-
tases and in various human melanoma cell lines, while we failed 
to detect any presence of HAS1. The amount of the secreted HA 
can be reduced by inhibition of calcineurin with CsA, while the 
inhibition of ERK1/2 exerted an opposite effect. HAS3 activity 
was likely regulated by reversible phosphorylation controlled by 
PP2B and ERK1/2. We also found that inhibition of ERK1/2 
activity increased the HA-guided migration of melanoma cells 
favouring lower molecular weight HA as a chemoattractant.
Materials and methods
Culturing melanoma and melanocyte cell lines. Human mela-
noma HT168 cell line (kind gift of professor József Tímár, 
Semmelweis University, Hungary) was established from 
A2058 cell line according to its metastasis formation in immu-
nosuppressed mice (29), while WM35 obtained from ATCC 
(ATCC® CRL-1661™, Manassas, VA, USA) originally was 
isolated from a primary cutaneous melanoma of radial growth 
phase (30). Cells were nourished with RPMI-1640 culture 
medium (Sigma-Aldrich, St. Louis, MO, USA) supplemented 
with 10% fetal bovine serum (PAA, Piscataway, NJ, USA), 
4.1 g/l glucose, 2 mmol/l L-glutamine (Gibco, Gaithersburg, 
MD, USA), penicillin (100 U/ml) and streptomycin 
(100 µg/ml). NHEM cell line (PromoCell GmbH, Heidelberg, 
Germany) was cultured in Melanocyte Medium (PromoCell 
GmbH) according to the instructions of the manufacturer. 
Cells were incubated at 37˚C in the presence of 95% air and 
5% CO2 atmosphere and 80% humidity in 25-cm2 flasks (Paa 
laboratories) until -70% confluence.
Inhibition of calcineurin and ERK 1/2. Activity of calcineurin 
and ERK1/2 was inhibited with the continuous application 
of 2 µM cyclosporine A (CsA) (Sigma-Aldrich) (dissolved in 
sterile DMSO) and 5 µM PD098059 (PD) (Sigma-Aldrich) 
(dissolved in sterile DMSO), respectively, started 2 days before 
confluence. Dmso was administered as vehicle-control but no 
alterations were shown in any of the experiments comparing 
with the untreated controls (data not shown).
bHABC-histochemistry and immunocytochemistry. Histo-
logical samples with melanoma metastases (mesenterial 
lymph node and lung lesions) as well as control tissues from 
healthy human bodies were collected from cadavers with 
the assistance of the Pathology and the Forensic Medicine 
Departments (n=3). The study was approved by the Ethics 
Committee of University of Debrecen, under licence number 
3244-7/2011. For morphological analysis, cell lines were 
cultured on rectangular cover glasses (Menzel-Gläser, Menzel 
GmbH, Braunschweig, Germany). Cadaver tissue samples and 
cell cultures were fixed in saint-marie's fixative (99% ethanol 
and 1% anhydrous acetic acid) for 24 or 1 h, respectively. 
Tissues were embedded into paraffin and 7-µm thick sections 
were cut. after removal of paraffin and rehydration in ethanol, 
PBS supplemented with 1% bovine serum albumin (BSA, 
amresco llC, solon, oH, Usa) at 37˚C for 1 h was applied to 
block nonspecific antibody binding. Ha was detected by using 
a biotinylated HA-binding complex in 5 µg/ml concentration 
(bHABC was kindly provided by R. Tammi and M. Tammi, 
Department of Anatomy, University of Kuopio, Kuopio, 
Finland) at 4˚C overnight. The reaction was visualized with 
Streptavidin-Alexa 555 (2 µg/ml, Invitrogen Corp., Carlsbad, 
Ca, Usa) for fluorescence microscopy. Cultures and tissues 
were mounted in Vectashield Hard Set mounting medium 
(Vector Laboratories Ltd., Peterborough, UK) containing 
DAPI to visualise the nuclei of cells. In cadaver tissue samples, 
monoclonal MelanA antibody (Novocastra Laboratories Ltd., 
Newcastle, UK) was used to demonstrate melanin-positive 
cells labelling with an Alexa 488 conjugated anti-mouse anti-
body (Invitrogen Corporation) at a dilution 1:1,000.
For HAS2, HAS3, RHAMM and CD44 immunocyto-
chemistry cell tissues were incubated with primary antibodies 
at a dilution described in Table i, at 4˚C overnight. For visuali-
sation of the primary antibodies Alexa Flour 488-conjugated 
INTERNATIONAL JOURNAL OF ONCOLOGY  48:  983-997,  2016 985
goat anti-rabbit (Invitrogen Corp.) and Alexa Fluor 
488-conjugated goat anti-mouse (Invitrogen Corp.) secondary 
antibodies were used at a dilution of 1:1,000. Samples were 
mounted in Vectashield Hard Set mounting medium (Vector 
Laboratories, Ltd.) containing DAPI to visualise the nuclei of 
cells. Photomicrographs of the samples were taken using an 
Olympus DP72 camera on a Nikon Eclipse E800 microscope 
(Nikon Corp., Tokyo, Japan). Images were acquired using 
cellSense Entry 1.5 software (Olympus, Shinjuku, Tokyo, 
Japan) using constant camera settings to allow comparison of 
fluorescent signal intensities.
Migration assays in Boyden chemotaxis chamber. Cells were 
washed twice in CMF-PBS, harvested with 0.25% trypsin 
(Sigma-Aldrich) and resuspended in RPMI-1640 medium in 
a density of 2x105 cells/ml. Lower wells of 48-well Boyden 
chemotaxis chamber (Neuro Probe Inc., Gaithersburg, MD, 
Usa) were filled with human umbilical cord Ha (1,600 kDa) 
or Streptomyces HA (300-800 kDa) (Sigma-Aldrich) dissolved 
in CMF-PBS at a concentration of 400 and 800 µg/ml, respec-
tively and covered with a polycarbonate filter (Neuro Probe 
Inc.) containing pores with a diameter of 3 µm. Cell suspen-
sion (50 µl) was inoculated into the wells on the top of the 
membrane and the chamber was incubated for 3 h at 37˚C in a 
humidified atmosphere (5% Co2-95% air). Non-migrated cells 
were removed from the surface of the membrane and after 
fixation in methanol, migrated cells were stained with 1% tolu-
idine blue (Sigma-Aldrich) dissolved in water. Membranes 
were air-dried and mounted with Pertex (Sigma-Aldrich). 
Absolute cell numbers were counted using a light microscope. 
Six-wells were counted in each experimental group and three 
independent assays were performed.
Measurement of cell proliferation with [3H]-thymidine 
labelling. Medium containing 1 µCi/ml [3H]-thymidine 
(185 GBq/mM) [3H]-thymidine (American Radiolabeled 
Chemicals, Inc. St. Louis, MO, USA) was added to the cells 
cultured in wells of 24-well plates for 16 h after 2 days of 
PD treatment. After washing with PBS, proteins were precipi-
tated with ice-cold 5% trichloroacetic acid for 20 min. After 
washing with PBS again, cells were harvested using 0.25% 
trypsin for 10 min. Cells were collected with centrifuga-
tion at 2,000 rpm, the pellet was resuspended in 10 µl 
CMF-PBS and placed into wells of special, opaque 96-well 
plates (Wallac, Perkin-Elmer Life and Analytical Sciences, 
Shelton, CT, USA). The plates were placed in an exsiccator 
containing phosphorous pentoxide in order to absorb mois-
ture. Prior to the measurements, 50 µl scintillation solution 
(MaxiLight; Hidex, Turku, Finland) was added to each well, 
and radioactivity was counted by a liquid scintillation counter 
(Chameleon Microplate Reader, Hidex). Measurements were 
carried out in 6 samples of each experimental group in 3 
independent experiments.
RNA isolation and reverse transcriptase PCR analysis. Cell 
cultures were dissolved in TRIzol (Applied Biosystems, Foster 
City, CA, USA) and after the addition of 20% RNase free 
chloroform, samples were centrifuged at 4˚C at 10,000 x g 
Table I. The antibodies used in the experiments.
Antibody Host animal Dilution for Dilution for Distributor; cat no.
  western blotting immunocytochemistry  
Anti-HAS1 Goat,  polyclonal 1:200 1:50 Santa Cruz Biotechnology Inc.,
    Santa Cruz, CA, USA
    sc-23145
Anti-HAS2 Rabbit,  polyclonal 1:200 1:50 Santa Cruz Biotechnology Inc.,
    Santa Cruz, CA, USA
    sc-66916
Anti-HAS3 Rabbit,  polyclonal 1:400 1:400 Abcam, Camridge, UK
    ab154104
Anti-HAS3 Rabbit,  polyclonal 1:400 1:1,000 Sigma-Aldrich, St. Louis, MO, USA
    SAB1101156
Anti-CD44 Mouse,  monoclonal 1:400 1:100 Gift from: Tammi & Tammi
    University of Kuopio, Finland
Anti-CD44 Mouse, monoclonal 1:400 1:100 R&D Systems,
 Clone: 2C5   Minneapolis, MN, USA
    BBA10
Anti-RHAMM Mouse,  monoclonal, 1:400 1:100 Novocastra, Newcastle, UK
 clone: 2D6   NCL-CD168
Anti-β-actin Mouse,  monoclonal, 1:10,000 - Sigma-Aldrich, St. Louis, MO, USA
 clone: AC-15   A5441
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for 20 min. Samples were incubated in 500 µl of RNase-free 
isopropanol at -20˚C for 1 h. after washing the centrifuged 
pellet by 70% ethanol the total RNA was resuspended in 
RNase-free water and stored at -20˚C. The assay mixture 
for reverse transcriptase reaction containing 2 µg RNA was 
performed by High Capacity RT kit (Applied Biosystems) 
according to the manufacturer's instructions. amplifications 
were performed in a thermal cycler (Labnet MultiGene™ 
96-well Gradient Thermal Cycler; Labnet International, 
Edison, NJ, Usa) in a final volume of 25 µl [containing 1 µl 
forward and reverse primers (0.4 µM), 0.5 µl dNTP (200 µM), 
and 5 U of Promega GoTaq® DNA polymerase in 1X reaction 
buffer] as follows: 95˚C, 2 min, followed by 35 cycles (dena-
turation, 94˚C, 1 min; annealing at optimised temperatures 
as given in Table ii for 1 min; extension, 72˚C, 90 sec) and 
then 72˚C, 10 min. The sequences of primer pairs, and further 
details of polymerase chain reactions, are given in Table II. 
PCR products were analysed by electrophoresis in 1.2% 
agarose gel containing ethidium bromide. GAPDH was used 
as internal control. Optical density of signals was measured 
by ImageJ 1.40 g freeware and results were normalised to the 
optical density of untreated control cultures.
Preparation of total cell lysates and western blot analysis. 
Cell cultures were washed in physiological NaCl solution and 
then harvested. After centrifugation (2,000 rpm, 10 min), cell 
pellets were suspended in 100 µl of homogenization RIPA 
(radioimmunoprecipitation assay)-buffer (150 mM sodium 
chloride; 1.0% NP40, 0.5% sodium deoxycholate; 50 mM Tris, 
pH 8.0) containing protease inhibitors [aprotinin (10 µg/ml), 
5 mM benzamidine, leupeptin (10 µg/ml), trypsine inhibitor 
(10 µg/ml), 1 mM PMSF, 5 mM EDTA, 1 mM EGTA, 8 mM 
Na-Fluoride, 1 mM Na-orthovanadate]. Samples were stored at 
-70˚C. suspensions were sonicated by pulsing burst for 30 sec 
at 40 A (Cole-Parmer, Illinois, USA). For western blotting, 
total cell lysates were used.
Samples for SDS-PAGE were prepared by the addition 
of Laemmli electrophoresis sample buffer (4% SDS, 10% 
2-mercaptoethanol, 20% glycerol, 0.004% bromophenol blue, 
0.125 M Tris-HCl pH 6.8) to cell lysates to set equal protein 
concentration of samples, and boiled for 10 min. Approximately 
40 µg of protein was separated by 7.5% SDS-PAGE gel for 
detection of HAS1, HAS2, HAS3, RHAMM, CD44, and actin. 
Proteins were transferred electrophoretically to nitrocellulose 
membranes. After blocking with 5% non-fat dry milk in 
Table ii. Nucleotide sequences, amplification sites, genBank accession numbers, amplimer sizes and PCR reaction conditions 
for each primer pair are shown. 
gene Primer Nucleotide sequence (5'-3') genBank iD annealing amplimer
    temperature size (bp)
Has1 sense CCT aCg agg Cgg Tgg TCT Nm_001297436 57˚C 306
  (1261-1278)
 Antisense GCA GAG GGA CGT AGT TAG CG 
  (1566-1547)
Has2 sense aCa ggC aTC TCa Cga aCC Nm_005328 49˚C 415
  (1479-1496)
 Antisense ATC TTG GCG GGA AGT AAA 
  (1893-1876)
Has3 sense TCg gCg aTT Cgg Tgg aCT Nm_001199280 57˚C 280
  (835-852)
 Antisense TGC TGG AGG AGG CTG TTG C 
  (1114-1096)
RHamm sense aaa gTT aag TCT TCg gaa TC Nm_001142556 46˚C 371
  (384-403)
 Antisense CCT TCT TGC TTA GCC ATC
  (754-737)
CD44 sense TTg Tgg CaT TTa TTC aTC ag Nm_000610.3 46˚C 321
  (4076-4095)
 Antisense GGT AGA CAG GGA GGA GCA
  (4396-4379)
gaPDH sense CCa gaa gaC TgT gga Tgg CC Nm_002046 54˚C 411
  (740-759)
 Antisense CTG TAG CCA AAT TCG TTG TC 
  (1150-1131)
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PBS, membranes were washed and exposed to the primary 
antibodies (Table i) overnight at 4˚C. Phospho-ser/Thr detec-
tion kit (Millipore, Billerica, MA, USA) was used to detect 
phosphorylation level of Ser/Thr amino acid side chains. After 
washing for 3x10 min in PBST, membranes were incubated 
with HRP conjugated anti-rabbit IgG (Bio-Rad Laboratories, 
CA, USA) in 1:1,500 or anti-mouse IgG (Bio-Rad Laboratories) 
in 1:1,500 dilution. Signals were detected by enhanced chemi-
luminescence (Millipore) according to the instructions of the 
manufacturer. signals were manually developed on X-ray film 
(Agfa-Gevaert Group, Mortsel, Belgium). Optical density of 
western blot signals was measured by using ImageJ 1.40 g 
freeware and the results were normalised to the values of 
untreated control cultures.
Statistical analysis. Optical density (OD) of RT-PCR and 
western blot results were normalised to the inner controls, 
then the ODs of the control samples of every experimental 
group and CsA or PD treated cultures of each melanoma cell 
line were used for statistical analysis. Statistical comparisons 
between control and test samples were performed by using 
student's paired t-test where statistical method reported signif-
icant differences among the groups (P<0.05). The data are 
representative of at least three different experiments. Where 
applicable, data are expressed as mean ± SEM.
Results
HA homeostasis of normal skin and melanoma metastasis. 
Although presence of HA around epidermal keratinocytes 
(31) and expression of HAS enzymes by these cells have been 
described long ago (32,33). Involvement of melanocytes in 
epidermal Ha homeostasis is less evident. Therefore, first we 
investigated the HA secretion of normal melanocytes locating 
in the stratum basale of human epidermis. We were able to 
demonstrate only a weak signal for HA in the basal cell layer 
Figure 1. Detection of hyaluronic acid, HAS2 and HAS3 in normal healthy tissues and malignant metastases. Row 1, normal skin, 2, mesenteric lymph node, 
3, melanoma metastasis from mesenteric lymph node, 4, normal lung, 5, melanoma metastasis from lung. (a) Ha affinity histochemistry. (B) Has2. (C) Has3 
immunohistochemistry. HA is labelled with Streptavidin-Alexa 555 (red), HAS2 and HAS3 anti-rabbit-Alexa 555 (red). Melanocytes and melanoma cells 
are shown with MelanA-Alexa 488 (green). Nuclei are demonstrated with DAPI (blue). Scale bar, 50 µm. Representative photomicrographs of 3 independent 
experiments are shown.
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of the epithelium (Fig. 1A-a.1). Expression of all the three 
HAS enzymes was also monitored. We failed to demonstrate 
either HAS1 (data not shown) or HAS2 in the epidermis of 
human skin tissue samples (Fig. 1B-b.1), but a well visible 
HAS3 immunopositivity was detected in the stratum basale 
where melanocytes reside accompanied with undifferentiated 
keratinocytes (Fig. 1C-c.1). As tumour invasion and motility 
are highly dependent on the ECM surrounding the malignant 
cells and HA has been proven to be one of the extracellular 
macromolecules which can be responsible for the regulation 
of infiltration of tissues in the vicinity of primary tumours 
(34), next we investigated HA and HAS content of melanoma 
samples. Two differently evolved metastases of melanoma 
were screened (mesenterial lymph node and lung lesions) and 
compared with normal tissues from healthy human cadavers. 
HA was modestly detectable in the normal lung and mesen-
teric lymph node (Fig. 1A-a.2 and a.4) but a strongly enhanced 
HA signal was observed either in lymph node (Fig. 1.A-a.3) 
or lung with melanoma metastases (Fig. 1A-a.5). HAS1 was 
detectable neither in normal skin, nor in malignant lesions 
(data not shown). The expression of HAS2 and HAS3 was 
not detectable with immunohistochemistry in normal lymph 
nodes (Fig. 1B-b.2 and c.2) or the lung (Fig. 1B-b.4 and c.4), 
but a strong signal of HAS2 immunopositivity was observed 
in lymph node melanoma metastases (Fig. 1B-b.3). In spite of 
the strong autofluorescence signal of elastic fibres in the lung, a 
well visible colocalization of HAS2 and MelanA was detected 
(Fig. 1B-b.5). Similarly to HAS2, HAS3 was not detected in the 
normal healthy tissues with this method (Fig. 1C-c.2 and c.4), 
but a pronounced expression was demonstrated in metastatic 
lymph nodes and lung metastases (Fig. 1C-c.3 and c.5). Strong 
HAS3 immunopositivity was seen close to the nuclei of 
MelanA expressing cells, as well as in the surrounding stromal 
cell population.
Regulation of HA secretion of in vitro melanocyte cell culture. 
Since the HA secretion and HAS expression were markedly 
altered in tissue samples with melanoma metastases we inves-
tigated the HA homeostasis of normal human melanocyte 
(NHEM) in a cell culture system. Similarly to the melanocytes 
locating in the stratum basale of epidermis, cultured melano-
cytes secreted only a low amount of HA, hardly detectable 
with affinity cytochemistry (Fig. 2a). as secretion of Ha can 
be regulated by reversible phosphorylation, we investigated 
the involvement of ERK1/2 in the HA production and we also 
aimed to identify the involvement of a possible PP, calcineurin 
in this process. PD098059 was administered as a MAPK and 
CsA as a calcineurin inhibitor. Inhibition of PP2B activity 
resulted in an undetectably low HA production of cultured 
melanocytes (Fig. 2A). In contrast, the inhibition of ERK1/2 
elevated the HA secretion of normal human melanocytes 
(Fig. 2A). These data suggest that the two enzymes exert the 
opposite effect on HA production of NHEM cells. In terms of 
the synthesising enzymes, mRNA of HAS1 was not present 
(data not shown), while the mRNAs of HAS2 and HAS3 were 
present in the NHEM cells (Fig. 2B), although only weak 
signals of protein expression were seen with western blot 
method (Fig. 2C). HAS2 was hardly detectable in NHEM 
(Fig. 2E) while HAS3 gave evident, strong signals with 
immunocytochemistry (Fig. 2F). Inhibition of calcineurin did 
not alter the mRNA expression of HAS3 and HAS2 (Fig. 2B 
and D), but reduction in the protein expression of the synthases 
was observed (Fig. 2C-F). Inhibition of MAPK pathway 
exerted different effect on HAS expression of NHEM cells. It 
did not alter the expression of HAS2 (Fig. 2B-E), but resulted 
in a modest elevation of the mRNA expression (Fig. 2B and D) 
and a pronounced increase of the protein expression of HAS3 
(Fig. 2C, D and F). Interestingly, a strong accumulation of 
HAS3 was visible around the nuclear area in NHEM cells 
after ERK1/2 inhibition (Fig. 2F).
Cells of both malignant melanoma cell lines secrete HA, but 
show various HAS expression patterns. It is already known 
that HA regulates the migration, proliferation and other cell 
biological features of malignant cells (5), so we aimed to 
detect the presence of this extracellular matrix component and 
to identify the HAS enzymes responsible for the production of 
HA in melanoma cell lines established from various stages of 
cutaneous melanoma.
HA was detected both intracellularly and pericellularly 
in the examined cell lines (Fig. 3A-a and d). The detected 
HA is the product of HAS2 and/or HAS3 enzymes because 
their mRNA (Fig. 4A and C) and protein expressions (Fig. 4B 
and D) were proven by reverse transcriptase PCR and western 
blot analyses, respectively. Neither mRNA nor protein expres-
sion of HAS1 was detected (data not shown). Similarly to 
NHEM, both melanoma cell lines expressed the mRNAs of 
both HAS enzymes (Fig. 4A) but the protein expression of the 
synthases showed slight differences. HAS2 protein expression 
was stronger in WM35 cells (Figs. 3B-a, 4B and D), while 
it remained weaker in HT168 cells (Figs. 3B-d, 4B and D). 
HAS3 protein expression showed the opposite pattern, it was 
stronger in HT168 cells and was almost undetectable in WM35 
cells (Figs. 3C-d, 4B and D). In both cell types, HAS3 formed 
filamentous arrangement in the cytoplasm and positive signals 
associated to the nuclear region were also detected (Fig. 3C-a 
and d).
Inhibition of ERK1/2 and PP2B altered the HA secretion 
of melanoma cells. Treatment of melanoma cells with 2 µM 
CsA notably decreased the HA secretion (Fig. 3A-b and e), 
while the inhibition of ERK 1/2 pathway with administration 
of 5 µM of PD098059 increased the HA production of both 
cell lines (Fig. 3A-c and f). Parallel with the HA production, 
application of CsA also decreased HAS2 protein expression 
(Figs. 3B-b and e, 4B and D). Presence of the dominantly 
expressed HAS3 isoform of aggressive metastatic HT168 
cells was significantly elevated by PD098059 treatment but 
no alteration was detected after the administration of CsA 
(Figs. 3C-c and f, 4B and D). Expression of HAS3 isoform 
showed only a modest decrease in WM35 cells after PP2B 
inhibition (Figs. 3C-b, 4B and D). At the level of ~60 kDa 
molecular weight we detected increased Ser/Thr phosphory-
lation at the presence of CsA. Administration of PD098059 
exerted an opposite effect it resulted in weaker signal for 
phosphorylated proteins at the same molecular weight. These 
observations suggest altered phosphorylation and the likeli-
hood of a consequent change in the enzymatic activity of 
HAS2 and/or HAS3 under the effect of the applied enzyme 
inhibitors (Fig. 4E and F).
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Figure 2. Detection of HA, HAS2 and HAS3 in NHEM cells in vitro. Untreated cells of NHEM, +CsA (continuous application of CsA in 2 µM) and +PD 
(continuous application of PD098059 in 5 µm) experimental groups were performed. (a) Ha affinity cytochemistry demonstrating secreted Ha in red 
(Streptavidin-Alexa 555). Scale bar, 20 µm. Representative photomicrographs of 3 independent experiments. (B) mRNA expression of HAS2 and HAS3 in 
NHEM cells. GAPDH was used as an inner control. Representative results from three independent experiments. (C) Protein expression level of HAS2 and 
HAS3 in NHEM cells. Actin was used as an internal control. Representative results from three independent experiments. Optical density of signals was mea-
sured and results were normalised to the optical density of controls. In (B and C) numbers below the signals represent integrated densities of signals determined 
by ImageJ software. (D) Statistical analysis of RT-PCR and western blot results. All data are the average of at least three different experiments. Statistical 
analysis was performed by student's t-test. The data were normalized on gaPDH or actin and are expressed as mean ± sEm. (E and F) immunocytochemistry 
of HAS2 and HAS3 appearing in red (Alexa 555). DAPI was used for visualisation of nuclei. Scale bar, 20 µm. Representative photomicrographs of three 
independent experiments.
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Involvement of receptors of hyaluronan binding in reversible 
dephosphorylation. It has been published that both CD44 
and RHAMM have important roles in the signal transduction 
of melanoma cells (35). In vitro, both of these receptors can 
Figure 3. Detection of Ha, Has enzymes in Wm35 and HT168 melanoma cell lines. (a) Ha affinity cytochemistry demonstrating secreted Ha in red 
(Streptavidin-Alexa 555). Untreated cells of WM35 (a), WM35 cells treated with 2 µM of CsA (b), and with 5 µM of PD098059 (c), untreated HT168 cells (d), 
HT168 cells treated with 2 µM of CsA (e), and with 5 µM of PD098059 (f). DAPI was used for visualisation of the nuclei. Scale bar, 20 µm. Representative 
photomicrographs of 3 independent experiments. (B and C) Immunocytochemistry of HAS2 and HAS3, positive signals appear in green (Alexa 488). Untreated 
cells of WM35 (a), WM35 cells treated with 2 µM of CsA (b), with 5 µM of PD098059 (c), untreated HT168 cells (d), HT168 cells treated with 2 µM of CsA (e), 
and with 5 µM of PD098059 (f). DAPI was used for visualisation of the nuclei. Scale bar, 20 µm. Representative photomicrographs of three independent 
experiments are shown.
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Figure 4. Detection of HAS enzyme expression and protein phosphorylation in WM35 and HT168 melanoma cell lines. (A) mRNA expression of HAS2 
and Has3 in Wm35 and HT168 cells. gaPDH was used as inner control. Representative data from five independent experiments. (B) Protein expression 
of Has2 and Has3 in Wm35 and HT168 cells. Representative results from five independent experiments. actin was used as an internal control. optical 
density of signals was measured and results were normalised to that of the controls. In (A and B) the numbers below signals represent integrated densities 
of signals determined by ImageJ software. (E) Ser/Thr phosphorylation was investigated by western blot analysis. Insert represents the signals at molecular 
weight of -60 kDa. Optical density of signals was measured and results were normalised to the optical density of controls. Representative results from three 
independent experiments. (C, D and F) Statistical analysis of RT-PCR and western blot results. The data are the average of at least three different experi-
ments. statistical analysis was performed by student's t-test. The data were normalized on gaPDH or actin and are expressed as mean ± sEm.
KATONA et al:  REGULATION OF HYALURONAN SYNTHESIS IN MELANOMA992
Figure 5. Investigation of the HA receptors RHAMM and CD44 in melanoma cell lines. (A) mRNA expression of RHAMM and CD44 in WM35 and HT168 
cells. GAPDH was used as an inner control. Representative data of three independent experiments. (B) Protein expression of RHAMM and CD44 in WM35 
and HT168 cells. Representative results from three independent experiments. Actin was used as an internal control. (C and D) Statistical analysis of RT-PCR 
and western blot results. all data are the average of at least three different experiments. statistical analysis was performed by student's t-test. all data were 
normalized on GAPDH or actin and are expressed as mean ± SEM. (E and F) Immunocytochemistry of RHAMM (E) under normal culture conditions of 
WM35 cells (a), after treatment with 2 µM of CsA (b), and 5 µM of PD098059 (c). Immunocytochemistry of CD44 (F) during normal culture conditions of 
HT168 cells (d), after treatment with 2 µM of CsA (e), and 5 µM of PD098059 (f). DAPI was used to visualise the nuclei of the cells. Scale bar, 50 µm.
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play a role in the regulation of the migration of melanoma 
cell lines. Expression of mRNA and protein of RHAMM 
and CD44 were demonstrated in both cell lines (Fig. 5A-D). 
RHAMM gave strong intracellular signals and the observed 
filamentous organization of the positivity suggests associa-
tion to cytoskeletal elements. CD44 also showed cytoplasmic 
positivity but membrane associated signals were also detected 
(Fig. 5E-a and F-a). Protein expression of RHAMM was 
higher in HT168 cell line than in WM35, while CD44 exhib-
ited similar expression pattern both in HT168 and WM35 
cell lines (Fig. 5B and D). Not every cell of the WM35 cells 
showed RHAMM positivity with immunocytochemistry 
(Fig. 5E-a). administration of 2 µm Csa did not significantly 
alter the protein expression of RHAMM in HT168 and in 
WM35 melanoma cells (Fig. 5B, D and E-b and e). In contrast, 
the application of 5 µM PD098059 intensely elevated the 
protein expression of RHAMM (Fig. 5B, D and E-c and f). 
Furthermore, none of the inhibitors had prominent effect on 
the CD44 protein expression (Fig. 5B, D and F).
Intra- and/or extracellular function of secreted HA. Since 
incorporated HA can be partly responsible for the regulation 
of proliferation of tumour cells (5) we investigated the effects 
of inhibitors on cellular division of WM35 and HT168 mela-
noma cells. We have previously published results that CsA 
reduces the proliferation of both cell lines (28). In contrast, 
PD098059 elevated the proliferation rate of HT168 cells 
(Fig. 6A).
As strong HA signals localized in the pericellular matrix 
of melanoma cells either in the melanoma cell cultures or 
in the tissue samples containing melanoma metastases, a 
supportive effect of HA on cell motility seemed very likely 
(5). Hence, we investigated the migratory properties and 
invasiveness of HT168 and WM35 melanoma cell lines. An 
in vitro migration assay was performed in Boyden chamber 
in the presence of hyaluronic acid (a higher, 1,600 kDa and 
a lower, 300-800 kDa molecular weight HA solution) as 
a chemoattractant. We did not find significant differences 
between the migrations of these cell lines towards different 
Figure 6. The effect of ERK1/2 and PP2B inhibition on proliferation and migration of malignant cells. (A) Proliferation activity was assessed by [3H]-thymidine 
incorporation, applied on the second day of continuous PD098059 treatment. Data represent mean ± standard error of the average of three independent experi-
ments. asterisk indicates significant (*P<0.05) increase in [3H]-thymidine incorporation as compared to the respective control. (B-D) Migration of different 
melanoma cell lines. Data represent mean ± standard error of the mean/average of 6 independent wells and presented in the average cell number of migrated 
cells. Representative data of 3 independent experiments. asterisks indicate significant (*P<0.05) decrease/increase in the number of migrated cells as compared 
to the respective control.
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size HA chemoattractants (Fig. 6B). As a result of the 2 µM 
CsA or 5 µM PD098059 treatments, the average number of 
the migrated HT168 cells toward lower molecular weight of 
Ha was elevated but no significant alteration was shown in the 
presence of 1,600 kDa HA (Fig. 6D). While the administration 
of CsA markedly diminished the migration of WM35 cells, the 
presence of PD098059 significantly facilitated the migration 
toward 300-800 kDa HA (Fig. 6C). In contrast, cell motility in 
the presence of the 1600 kDa Ha was not significantly altered 
by PD098059 administration (Fig. 6C).
Discussion
Melanoma is one of the most aggressive and rapidly invading 
tumours with the worst prognosis in clinical dermatology. 
Formation of metastasis of malignantly transformed mela-
nocytes is highly dependent on the cell surface receptor 
composition and any alterations in the composition and/or 
organization of the pericellular matrix (2-4). Presence of HA at 
the vicinity of keratinocytes has been proved in human skin (36) 
and its function in the metastasis formation during melanoma 
progression has also been demonstrated (5,37). Accumulation 
of HA and the activation of HA synthases during skin injury 
(31) or by keratinocyte growth factor (38) play a crucial role in 
the reconstruction of the integrity of epidermis and the subse-
quent tissues. Different molecular sized HA was produced by 
each of the HAS1, -2 and -3, proven to exert diverse effects on 
the normal life cycle of cells and can influence invasiveness of 
malignant cells (39). The altered expression of each HAS has 
been published in different stages of melanoma and HA accu-
mulation surrounding primer tumours was also detected (37). 
In the present study, we proved the presence of HA and HAS3 
in the MelanA positive melanocytes along with a weak expres-
sion of HAS2 in the stratum basale of the normal epidermis. 
In contrast to the data published (37), we found elevated HA, 
HAS2 and also HAS3 expression but did not detect any HAS1 
in malignant lesions such as lung and mesenteric lymph node 
metastases. The lack of HAS1 enzyme can be a result of meta-
bolic differences of the three HAS enzymes, as HAS1 requires 
higher concentration of HA precursors (40). Nonetheless, abun-
dant expression and prognostic correlation with the presence 
of HAS1 was found in case of breast cancer (41). Some studies 
indicated that inhibition of HA synthesis and accumulation 
of HA in the cell coat with 4-methyl-umbelliferion can also 
diminish migration of some type of tumour cells such as BF16 
melanoma cell lines while it has no effect on other malignant 
cells such as breast cancer cells (42). These observations may 
reflect on differences in the enzymatic source of the Ha-rich 
pericellular matrix in various malignancies. There are data 
demonstrating, that overexpression of HAS3 results in increase 
of cell surface HA and enhances cell locomotion (43) and 
mutations and aberrant splicing of HAS may alter the migra-
tion of tumour cells (18). Clearly, the regulation of the HA 
production by various HAS enzymes in different malignant 
tissues is an important factor which should have a deep impact 
on the behaviour of malignant cells. Therefore, we investigated 
the molecular regulation of HA synthesis focusing on Ser/Thr 
phosphorylation of HAS enzymes.
HA stimulates migration of melanoma cell lines in vitro via 
the interaction with CD44 and RHAMM (44-46). A variety of 
signalling pathways have been identified which associate with 
RHAMM (47-51) and CD44 (52-54). CD44 phosphorylation 
is one of the most important posttranscriptional modifications 
in the activation of cell-cell or cell-matrix interactions during 
migration (14). Another HA receptor, RHAMM regulates 
signalling cascades which are linked to the MAP kinase 
pathway, whose ser/Thr specific protein kinase elements can 
be mutated in melanoma cells (55). ERK1/2 regulates prolif-
eration of cancer cells (56) via a direct contact formed with the 
RHAMM-HA complex (15,16). Thus, the HA induced signal 
transduction and ERK have a well-defined role in tumour 
progression, but only sporadic data exist in connection with 
HA synthases. It has been proven that HAS2 can be Ser/
Thr phosphorylated which may modify the HA synthesis of 
cells (57). As ERK1/2 has an indirect link to HA homeostasis 
via RHAMM binding, and it could be a question of interest 
whether this RHAMM-HA-ERK1/2 complex has any effect 
on HA synthesis (58). We found that the inhibition of ERK1/2 
increased the secreted HA and elevated the expression of 
HAS3 in melanoma cell cultures. A similar phenomenon was 
described in a synoviocyte cell culture system (59). We also 
demonstrated, that ERK1/2 inhibition reduced the Ser/Thr 
phosphorylated proteins at the molecular weight of 60 kDa, 
which suggests that HAS2 and/or HAS3 can be targets of ERK 
signalling. It was an interesting phenomenon that HAS3 immu-
nopositivity showed a filamentous organization and signals 
also appeared close to the nuclear area of the cells in mela-
noma cell lines. NHEM cells showed a strong accumulation of 
HAS3 around the nuclear area after the inhibition of ERK1/2. 
These findings strengthen the idea that ERK signalling path-
ways play role in the regulation of HA synthases (58) and 
suggest that maPK-signalling may influence the intracellular 
localization of HAS enzymes, particularly HAS3. Another 
interesting finding was that the ERK inhibition enhanced 
migration towards smaller HA. As HAS3 produces lower 
molecular weight HA, this observation further strengthens the 
probability of the functional link of ERK1/2 and this isoform 
of HAS (60). Smaller HA (40-70 kDa) can be incorporated to 
cells by endocytosis (17) and enhances proliferation, thus the 
increased level of HA after ERK inhibition can be one of the 
factors that have positive effect on cellular division as well (5). 
Indeed, we found that upon inhibition of MAPK pathway with 
PD098059, proliferation of the highly aggressive HT168 cells 
significantly increased.
We have published that inhibition of the Ca-calmodulin 
dependent cellular PP, PP2B also known as calcineurin, with 
cyclosporine A attenuated proliferation and enhanced expres-
sion and phosphorylation of ERK1/2 in HT168 and WM35 
cell lines (28). In the present study we aimed to explore if the 
inhibition of this PP exerts any effect on the HA homeostasis 
of melanoma cells. To the best of our knowledge, there are no 
published experimental data on the involvement of PPs in the 
regulation of HA synthesis so far. Here we demonstrated that 
the inhibition of PP2B (calcineurin), reduced the amount of 
HA both in NHEM and melanoma cell lines and we detected 
a significant increase of ser/Thr phoshoproteins at 60 kDa, the 
molecular weight of HAS2 and HAS3, during administration 
of CsA. These observations together with our above mentioned 
previous findings suggest, that PP2B may influence phosphor-
ylation of the HAS enzymes indirectly, via modulation of the 
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activity of MAPK pathway. Moreover, the inverse correlation 
between the amount of the phosphoproteins at 60 kDa to the 
detected amount of HA raise the probability that phosphory-
lation of HAS enzymes at the Ser/Thr residues, which are 
targeted either directly or indirectly by an ERK1/2-PP2B axis, 
have negative effect on their biosynthetic activity in the inves-
tigated melanoma cell lines. Although this hypothesis requires 
further experimental support, Vigetti et al (61) observed a 
similar phenomenon in aortic smooth muscle cells, when 
activation of MAPK caused phosphorylation on threonine 110 
in HAS2 and enzymatic activity became markedly lowered as 
the consequence of this posttranslational modification (61). in 
contrast, we found that pharmacological inhibition of MAPK 
pathway enhanced HA synthesis, while Bourguignon et al 
reported, that ERK activation mediated serine phosphorylation 
increased the HA secretion by all the three HAS isoforms (62). 
Clearly, the site of the phosphorylation has deep impact on the 
activity of HAS enzymes, it can either increase or decrease it. 
moreover, certain cell specific aspects of the final outcome of 
HAS phosphorylation should also be taken into consideration.
Expression of the HA receptors RHAMM and CD44 
has been proven both in malignant melanoma and in normal 
melanocytes (5,63). RHAMM can be in a direct interaction 
with intracellular HA through which it can bind to ERK1/2. 
Therefore, the elevation of the expression of this HA binding 
receptor together with the strong HA signals upon ERK inhibi-
tion in both melanoma cell lines can be factors which promote 
migration and/or proliferation (5). Either the HA receptor 
RHAMM or ERK1/2 can bind to microtubules in the cells. 
Both of RHAMM and HAS3 immunocytochemistry gave a 
sort of filamentous arrangement in the cells in our experi-
ments, supporting the probability of RHAMM-ERK-HAS3 
crosstalk in both investigated melanoma cell lines (64). The 
expression of Has3 protein was significantly lower in Wm35 
cells which may correlate with the milder phenotype of this 
cell line as it was isolated from early stage of melanoma 
progression (65).
In conclusion, our results reflect on differences in the 
chemoattractant behaviour of HA with various molecular 
weights. Moreover, a complex regulatory mechanism via 
protein phosphorylation of HAS2 and HAS3 is suggested in 
which PP2B plays a promoting role, while MAPK pathway 
attenuates HA production and RHAMM protein expression 
in WM35 and HT168 melanoma cell lines. This latter obser-
vation may suggest that application of MAPK-ERK pathway 
inhibitors requires careful, personalized therapeutic design in 
case of melanoma patients.
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